Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

BACKGROUND: Persons with acute leukemia relapsing after allotransplant and who respond to anti-leukemia interventions are at high risk of a second relapse. We studied the impact of minimal residual disease (MRD)- and graft-vs.-host disease (GvHD)-guided multiple consolidation chemotherapy and donor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chen-Hua, Wang, Yu, Wang, Jing-Zhi, Chen, Yu-Hong, Chen, Yao, Wang, Feng-rong, Sun, Yu-Qian, Mo, Xiao-Dong, Han, Wei, Chen, Huan, Zhang, Xiao-hui, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024494/
https://www.ncbi.nlm.nih.gov/pubmed/27629395
http://dx.doi.org/10.1186/s13045-016-0319-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024494/
https://www.ncbi.nlm.nih.gov/pubmed/27629395
http://dx.doi.org/10.1186/s13045-016-0319-5

Ejemplares similares